drugset / Trial / NCT04486326

Crofelemer for Functional Diarrhea

NCT04486326

Phase 4 Terminated 17 enrolled Beth Israel Deaconess Medical Center
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objectives of this study are to evaluate the clinical response of patients with diarrhea to crofelemer relative to placebo and evaluate the overall safety and tolerability of crofelemer in the treatment of diarrhea.

Timeline

Start
2020-08-20
Primary completion
2022-09-23
Completion
2022-09-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Crofelemer Small molecule 125 mg

Indications